• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    63 Biggest Movers From Yesterday

    6/17/22 3:38:26 AM ET
    $ACIU
    $ACLX
    $ACOR
    $ADN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACIU alert in real time by email

    Gainers

    • Advent Technologies Holdings, Inc. (NYSE:ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
    • Electric Last Mile Solutions, Inc. (NASDAQ:ELMS) gained 100.3% to close at $0.2820 after declining around 15% on Wednesday. Electric Last Mile Solutions recently announced plans to file for Chapter 7 bankruptcy.
    • Sidus Space, Inc. (NASDAQ:SIDU) shares climbed 63% to close at $7.63. Sidus Space shares jumped 225% on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) jumped 54.5% to close at $0.6185 after the company announced Esteve Pharmaceuticals GmbH launched INBRIJA in Germany.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) gained 42.4% to close at $2.42 following’s Wednesday IPO.
    • Vivakor, Inc. (NASDAQ:VIVK) gained 40.7% to close at $2.49 after the company announced it signed a definitive agreement to acquire Silver Fuels Delhi and White Claw Colorado City.
    • Cango Inc. (NYSE:CANG) jumped 40.2% to close at $3.14.
    • Pennsylvania Real Estate Investment Trust (NYSE:PEI) shares rose 34.8% to close at $5.32.
    • Decisionpoint Systems, Inc. (NYSE:DPSI) gained 34.9% to settle at $6.11.
    • Akanda Corp. (NASDAQ:AKAN) jumped 32.6% to close at $1.23.
    • Alpha Tau Medical Ltd. (NASDAQ:DRTS) gained 25.4% to close at $12.41.
    • Lytus Technologies Holdings PTV. Ltd. (NYSE:LYT) climbed 24.9% to close at $21.25. Lytus Technologies priced its IPO at $4.75 per share.
    • Zhong Yang Financial Group Limited (NASDAQ:TOP) gained 24.8% to settle at $38.70.
    • Troika Media Group, Inc. (NASDAQ:TRKA) jumped 23.8% to settle at $0.9026.
    • Akero Therapeutics, Inc. (NASDAQ:AKRO) jumped 22% to close at $10.37. Akero Therapeutics announced a $25 million equity investment by Pfizer at $9.90 per share.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) jumped 20.7% to close at $14.30.
    • Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) climbed 19.7% to settle at $0.9751.
    • Alfi, Inc. (NASDAQ:ALF) jumped 18.5% to close at $1.28.
    • CinCor Pharma, Inc. (NASDAQ:CINC) rose 18.2% to close at $17.90. CinCor Pharma recently dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD).
    • SeaChange International, Inc. (NASDAQ:SEAC) jumped 17.3% to close at $0.6101.
    • Radius Health, Inc. (NASDAQ:RDUS) gained 17.1% to settle at $8.49.
    • Selecta Biosciences, Inc. (NASDAQ:SELB) jumped 16.5% to close at $1.34. Selecta Biosciences Director Carrie Smith Cox reported a purchase of 130,000 shares at $1.15 per share.
    • NextNav Inc. (NASDAQ:NN) surged 15.6% to close at $2.97. Nextnav 10%+ owner Wocap Global Opportunity Investment Partners, L.P. reported the purchase of 8,346,571 shares at at average price of $3.93 per share in Form 4 Filing on Wednesday.
    • Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) gained 15.4% to close at $10.19.
    • VIA optronics AG (NYSE:VIAO) gained 11.6% to close at $2.51.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) rose 11.5% to settle at $0.3010.
    • Bone Biologics Corporation (NASDAQ:BBLG) shares gained 10.8% to close at $1.33.
    • Bon Natural Life Limited (NASDAQ:BON) gained 7.9% to close at $3.70.
    • Redbox Entertainment Inc. (NASDAQ:RDBX) shares gained 6.7% to close at $11.69 after gaining around 9% on Wednesday.

     

    Losers

    • EJF Acquisition Corp. (NASDAQ:EJFA) shares dropped 42.7% to close at $5.50.
    • Ebix, Inc. (NASDAQ:EBIX) shares tumbled 37.7% to close at $14.59 on Thursday.
    • PROG Holdings, Inc. (NYSE:PRG) declined 30.9% to close at $16.57 after the company cut FY22 adjusted EPS and sales guidance below estimates.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) fell 28.8% to close at $0.9116.
    • SpringBig Holdings (NASDAQ:SBIG) declined 28.7% to close at $3.21. springbig completed its merger with Tuatara Capital.
    • Mobiquity Technologies, Inc. (NASDAQ:MOBQ) fell 25.5% to close at $1.11.
    • AirSculpt Technologies, Inc. (NASDAQ:AIRS) tumbled 22.3% to close at $6.35. Morgan Stanley downgraded AirSculpt Technologies from Overweight to Equal-Weight and lowered the price target from $17 to $8.5.
    • Winc, Inc. (NYSE:WBEV) dropped 21.9% to close at $1.50.
    • Renovare Environmental, Inc. (NASDAQ:RENO) fell 21.8% to close at $0.1721.
    • Ambow Education Holding Ltd. (NYSE:AMBO) declined 21.8% to close at $0.36.
    • Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) fell 19.7% to close at $6.15.
    • Eros Media World Plc (NASDAQ:EMWP) dropped 18.3% to settle at $2.10.
    • AC Immune SA (NASDAQ:ACIU) fell 17.8% to close at $2.35 after the company announced crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer's disease.
    • Aquestive Therapeutics, Inc. (NASDAQ:AQST) dipped 17.8% to close at $0.7268. Aquestive Therapeutics announced topline results from the first three arms of Part 3 of the EPIPHAST study for its AQST-109 epinephrine oral film for allergic reactions, including anaphylaxis.
    • Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE:VLRS) fell 17.6% to close at $9.29.
    • Sonder Holdings Inc. (NASDAQ:SOND) dropped 17.4% to settle at $1.28.
    • Aspen Group, Inc. (NASDAQ:ASPU) fell 17.2% to close at $0.82.
    • StealthGas Inc. (NASDAQ:GASS) declined 17.1% to close at $3.39.
    • Beazer Homes USA, Inc. (NYSE:BZH) fell 16.9% to close at $10.65. B. Riley Securities maintained Beazer Homes USA with a Buy and lowered the price target from $23 to $19.
    • Yellow Corporation (NASDAQ:YELL) dropped 16.5% to close at $2.83.
    • FTC Solar, Inc. (NASDAQ:FTCI) fell 16.3% to settle at $4.16.
    • Outbrain Inc. (NASDAQ:OB) dropped 16.2% to close at $4.66. Jefferies maintained Outbrain with a Buy and lowered the price target from $9 to $8.
    • Shift Technologies, Inc. (NASDAQ:SFT) declined 16.2% to close at $0.6099.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) fell 15.8% to settle at $4.32.
    • Connexa Sports Technologies Inc. (NASDAQ:CNXA) fell 15.2% to close at $1.67.
    • Embark Technology, Inc. (NASDAQ:EMBK) fell 14.4% to close at $0.5575.
    • Arcellx, Inc. (NASDAQ:ACLX) fell 14% to close at $15.02. Arcellx priced an upsized underwritten follow-on offering of 7 million at $16 per share from the original 4 million shares.
    • IsoPlexis Corporation (NASDAQ:ISO) fell 13.6% to close at $2.10.
    • Sally Beauty Holdings, Inc. (NYSE:SBH) fell 12.7% to close at $11.75 after Morgan Stanley downgraded the stock from Equal-Weight to Underweight and lowered its price target from $19 to $12.
    • Cepton, Inc. (NASDAQ:CPTN) fell 11% to close at $1.29. Cepton, is set to join the Russell 3000® Index.
    • Green Giant Inc. (NASDAQ:GGE) declined 10.9% to close at $1.06.
    • SOPHiA GENETICS SA (NASDAQ:SOPH) fell 10.7% to close at $2.50.
    • Koninklijke Philips N.V. (NYSE:PHG) fell 9.6% to close at $20.44.
    • Missfresh Limited (NASDAQ:MF) fell 9.2% to close at $0.2249.
    Get the next $ACIU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACIU
    $ACLX
    $ACOR
    $ADN

    CompanyDatePrice TargetRatingAnalyst
    Aquestive Therapeutics Inc.
    $AQST
    4/24/2026$8.00Outperform
    Oppenheimer
    NextNav Inc.
    $NN
    4/16/2026$25.00Perform → Outperform
    Oppenheimer
    Rani Therapeutics Holdings Inc.
    $RANI
    4/14/2026$9.00Buy
    Lake Street
    Controladora Vuela Compania de Aviacion S.A.B. de C.V.
    $VLRS
    4/13/2026$7.60Buy → Neutral
    Goldman
    FTC Solar Inc.
    $FTCI
    3/6/2026$12.50 → $8.00Buy
    TD Cowen
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    Arcellx Inc.
    $ACLX
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    Sally Beauty Holdings Inc. (Name to be changed from Sally Hold
    $SBH
    1/21/2026$19.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chen Jing Veronica

    3 - Bon Natural Life Ltd (0001816815) (Issuer)

    4/23/26 6:15:32 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Cox Erin Nealy

    4 - Sally Beauty Holdings, Inc. (0001368458) (Issuer)

    4/22/26 5:00:10 PM ET
    $SBH
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Van Well Daan

    4 - SOPHiA GENETICS SA (0001840706) (Issuer)

    4/21/26 4:04:38 PM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACIU
    $ACLX
    $ACOR
    $ADN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-13) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/19/2022. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy

    12/21/22 4:37:57 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/22/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy

    12/23/21 5:39:20 PM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

    - IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma - - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alp

    4/23/26 9:02:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

    ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatmentApproximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable, non-metastatic diseaseThe trial is a key pillar of Alpha Tau's global clinical expansion strategy in Europe, alongside the ongoing IMPACT multicenter pancreatic cancer trial in the United States First pat

    4/23/26 9:01:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction

    April 23, 2026   Bridge Plus was designed for rare, life-threatening emergencies to help control bleeding during superior vena cava (SVC) tears, which occur in <0.5% of lead extraction procedures [1] but require immediate intervention Bridge Plus allows for rapid response when every second counts by deploying in under two minutes [2] and stopping up to 90% blood loss [3], helping stabilize patients with 30 minutes of hemostasis [4]Bridge Plus was built upon proven Bridge Occlusion Balloon technology, used in more than 50,000 U.S. procedures [5,*], with evidence showing improved survival when staged in advance [6,**] Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a globa

    4/23/26 9:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $257,211 worth of shares (105,848 units at $2.43), increasing direct ownership by 2% to 6,592,059 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/16/26 6:43:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

    4/24/26 8:31:20 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextNav upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded NextNav from Perform to Outperform and set a new price target of $25.00

    4/16/26 7:59:04 AM ET
    $NN
    Industrial Machinery/Components
    Industrials

    Lake Street initiated coverage on Rani Therapeutics with a new price target

    Lake Street initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $9.00

    4/14/26 9:27:33 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACIU
    $ACLX
    $ACOR
    $ADN
    SEC Filings

    View All

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    4/23/26 9:02:03 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Cango Inc.

    6-K - Cango Inc. (0001725123) (Filer)

    4/22/26 4:04:20 PM ET
    $CANG
    Computer Software: Prepackaged Software
    Technology

    Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

    4/21/26 4:18:08 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Leadership Updates

    Live Leadership Updates

    View All

    Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we

    4/9/26 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sally Beauty Holdings Appoints Adrianne Lee as Chief Financial Officer

    Marlo Cormier to Step Down to Pursue Other Opportunities Reaffirms Second Quarter and Fiscal Year 2026 Guidance Sally Beauty Holdings, Inc. (NYSE:SBH) ("the Company") today announced that Adrianne Lee has been appointed Senior Vice President and Chief Financial Officer, effective April 28, 2026. Ms. Lee succeeds Marlo Cormier, who will be leaving the company, effective April 11, 2026, to pursue other opportunities. Ms. Lee brings significant relevant experience to the role, most recently serving as President and CFO at Bed Bath & Beyond. Ms. Lee joined Bed Bath & Beyond as CFO in 2020 and became Chief Administrative Officer in 2024 and President in 2025. Prior to that, she held senior

    4/2/26 6:45:00 AM ET
    $SBH
    Other Specialty Stores
    Consumer Discretionary

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AC Immune SA

    SC 13G/A - AC Immune SA (0001651625) (Subject)

    12/13/24 5:15:16 PM ET
    $ACIU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by StealthGas Inc.

    SC 13D/A - StealthGas Inc. (0001328919) (Subject)

    12/9/24 3:53:05 PM ET
    $GASS
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by NextNav Inc.

    SC 13D/A - NEXTNAV INC. (0001865631) (Subject)

    12/6/24 6:03:25 PM ET
    $NN
    Industrial Machinery/Components
    Industrials

    $ACIU
    $ACLX
    $ACOR
    $ADN
    Financials

    Live finance-specific insights

    View All

    SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

    BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi

    4/21/26 8:00:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opendoor 1Q26 Financial Open House on May 7th, 2026

    SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Today, Opendoor Technologies Inc. ("Opendoor") (NASDAQ:OPEN) announced that it will report first quarter 2026 financial results for the period ended March 31, 2026 following the close of the market on Thursday, May 7, 2026. Modernizing Investor AccessOn May 7, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company's business and financial results. We believe in building in the open. The Financial Open House replaces the traditional earnings conference call with a video event, including a live segment for shareholder Q&A. Shareholder Q&AWe invite shareholders to participa

    4/16/26 9:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    Beazer Homes USA, Inc. to Webcast Its Fiscal Second Quarter Results Conference Call on Thursday, April 30, 2026

    Beazer Homes (NYSE:BZH) (www.beazer.com) has scheduled the release of its financial results for the quarter ended March 31, 2025 on Thursday, April 30, 2026 after the close of the market. Management will host a conference call on the same day at 5:00 PM ET to discuss the results. The public may listen to the conference call and view the Company's slide presentation on the "Investor Relations" page of the Company's website, www.beazer.com. In addition, the conference call will be available by telephone at 800-475-0542 (for international callers, dial 630-395-0227). To be admitted to the call, enter the pass code "8571348." A replay of the conference call will be available, until 11:59 PM E

    4/14/26 6:30:00 AM ET
    $BZH
    Homebuilding
    Consumer Discretionary